News coverage about Innoviva (NASDAQ:INVA) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Innoviva earned a news impact score of 0.22 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.396962801007 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

A number of research analysts have recently issued reports on INVA shares. Zacks Investment Research downgraded Innoviva from a “hold” rating to a “sell” rating in a report on Monday, July 3rd. ValuEngine cut Innoviva from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Stifel Nicolaus reiterated a “neutral” rating on shares of Innoviva in a research report on Friday, September 15th. Robert W. Baird reiterated a “neutral” rating and set a $13.00 price objective (up previously from $11.00) on shares of Innoviva in a research report on Thursday, July 27th. Finally, Cowen and Company set a $16.00 price objective on Innoviva and gave the company a “buy” rating in a research report on Friday, July 28th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Innoviva currently has an average rating of “Hold” and an average target price of $15.00.

Innoviva (NASDAQ:INVA) traded up 1.94% during mid-day trading on Thursday, reaching $14.73. The company had a trading volume of 415,929 shares. The firm has a market capitalization of $1.61 billion, a PE ratio of 18.53 and a beta of 2.60. The stock’s 50-day moving average price is $13.58 and its 200 day moving average price is $12.94. Innoviva has a 52 week low of $8.67 and a 52 week high of $14.87.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.30 EPS for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.02. Innoviva had a negative return on equity of 27.37% and a net margin of 52.56%. The company had revenue of $58.60 million during the quarter, compared to analysts’ expectations of $50.53 million. During the same quarter in the previous year, the firm posted $0.13 EPS. The firm’s revenue was up 80.3% compared to the same quarter last year. On average, equities research analysts predict that Innoviva will post $1.16 EPS for the current year.

WARNING: “Innoviva (INVA) Earns News Sentiment Score of 0.22” was posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at http://www.mareainformativa.com/innoviva-inva-earns-news-sentiment-score-of-0-22/117716/.

Innoviva Company Profile

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Insider Buying and Selling by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Stock Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related stocks with our FREE daily email newsletter.